🔗 Share this article

While the US proceeds with historic adjustments to its vaccination recommendations, one figure appears unexpectedly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by questioning coronavirus vaccinations during the pandemic and has zeroed in on possible deaths following Covid vaccination in her short time at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Immunization Schedule

Public health authorities planned to unveil major revisions to the pediatric vaccination calendar in December, bringing the US with Denmark’s vaccine program, it is understood – a significant shift that would put the US out of alignment with much of the international standard with little proof for benefit. The announcement has been delayed until the coming year.

Instead of the director of the vaccine center, Tracy Beth Høeg is listed to address the audience at the gathering. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the division this year.

Consolidating Power at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the drug and biologics divisions as Dr. Høeg and Prasad strengthen their influence at the agency – and it points to a renewed priority upon reevaluating long-standing immunizations at the FDA.

Høeg has frequently advocated for discontinuing some pediatric shot schedules in the US so as to align more like the Danish model, a country with nationalized medicine and a population about the population of Wisconsin’s.

In her initial statements, she has kept her attention on vaccines – usually the purview of Prasad, head of the FDA’s CBER – rather than medication approval.

Concerns Over Expertise

Høeg has little discernible background in pharmaceutical research, regulation or administrative roles, which has been customary for past directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the FDA chief and CBER since March.

“It seems she lacks to have the requisite experience” for leading the CDER, stated a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She lacks experience in running a sizeable institution. She lacks background in industry regulation.”

Past directors of the center would “be deeply familiar with regulatory frameworks and the research of medication creation”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that prior appointees who led CBER have had.”

The drug center has an enormous portfolio at the FDA, she pointed out.

“Everybody just focuses on the innovative therapies, but the off-patent medication office clears thousands of off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and more, and every single one have to be looked after,” she noted. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

There is also, a significant management element to the role, which manages in excess of 5,000 employees. “It’s a massive administrative position, if you do it right,” the former official added.

Official Statement and Contentious Policies

When asked about questions about Dr. Høeg's qualifications and whether this selection signifies more teamwork among FDA leaders on immunizations, a representative responded that the “concerns stem from incorrect premises”.

“Her experience aligns with the functions of her job,” the official explained, pointing to the time Høeg spent counseling the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg inherits the agency head's recently launched expedited review system, a controversial rapid therapy clearance system that reportedly worried her predecessors. “How are these medications being chosen for this fast-track system? Who makes the choices?” Howard asked. “There’s a lot of secrecy happening at the FDA right now.”

Overall, he said, “the agency appears to be shifting towards laxer oversight of all drugs, aside from vaccines.”

Public History on Immunizations

Regarding vaccines, Høeg has a more documented, if problematic, history, Howard have noted. She released a analysis using non-validated volunteer-provided data to assess the rate of heart inflammation following COVID-19 vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “policy goals” for the new administration included altering guidelines for new vaccines and halting “non-essential” vaccines, she stated after the election on a podcast. At the FDA, Dr. Høeg has reportedly floated the idea of excluding adolescent males from receiving Covid vaccines.

“She’s an all-around true believer who begins with her beliefs and tailors the evidence to retrofit the evidence in a highly deceptive, dishonest way,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg aligned with other skeptics, {like|